Replies to post #115534 on Biotech Values

[mcbio]

I know the field and data well. My main worry was something we don't know, like ARNA's rat. It doesn't appear there is any. My cost average was about $6 before today, so when it fell into $6 range, I had no hesitation because the path is clearer to me than before the CRL. I am not a trader on this stock, so I have time. I hedged with option for this particular binary event, most likely won't from now on.

Sure there is risk, but risk worth of taking based on my knowledge of the area. MNTA has risk too, but one I am willing to take as well. DON'T BET THE FARM. Since it works in Gaucher, PLX sure can get to ERT for Fabry, MPSI, Pompe. They didn't have lots of resources before, and the trials in these areas last very long. They could only work on one at time. Plant cell based is a giant leap for recombinant protein production.

I listened to the CC and I thought management came across as being confident they'll be able to address the CRL. One of the biq questions that came up during Q&A related to hypersensitivity and management claimed that they've seen a 7% hypersensitivity rate in their trials of Uplyso, which is similar to Cerezyme. Also, the magnitude of the hypersensitivity is apparently similar as well.

The Yahoo crowd seems to think that a financing will be forthcoming soon. Do you see a risk of financing this year? I know PLX said they have $36M in cash as of 12/31/10, which is sufficient for 12 months, but, given the delay now, perhaps it's not too unreasonable to think that a financing could be forthcoming before we ultimately hear back from the FDA again. As someone who is just watching from the sideline, I think I'd be inclined to wait for this before considering a position.